Abstract
The US National Institutes of Health is launching the first human study of a universal flu vaccine, developed by National Institute of Allergy and Infectious Diseases scientists. Called H1ssF_3928, the vaccine is a ferritin nanoparticle dotted with part of hemagglutinin, one of two main proteins on the surface of the flu virus. NIH hopes to understand whether the vaccine can train the immune system to respond to a range of influenza subtypes and whether that response differs among age groups. The first results of the study are expected in early 2020.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
